Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Application is filed with ANVISA but timing remains unclear due to uncertainty whether approvals will be processed in batches or in filing order. ANVISA's typical 24-36 month timeline may compress for this priority drug but remains uncertain.
Patent for semaglutide expires in March but ongoing litigation creates uncertainty on market formation timing. Management declined to provide specific timeline for domestic market launch.
Constant currency revenue declined 5% due to third-party supplier disruption. Management expects improvement in Q4 but acknowledged possibility of continued impact if supplier issues persist beyond Q3.
Management acknowledged U.S. filing ramp-up is taking longer than previously communicated. ANDA filings will only reach 10 in FY27 and 15 in subsequent year, with profitability recovery lagging behind.
